Opus Genetics is trading at $3.81 (-10.66%) as technology and growth-stock selling intensified amid investor reassessment of AI spending and data-center expansion risks.
- On November 5, 2026, Reuters reported the Nasdaq fell nearly 4%, with tech stocks suffering their worst decline since June.
- Biotech shares also weakened, with XBI down 5.19%.
- The company completed dosing for 11 trial participants; that positive update does not explain the drop.